期刊文献+

肺耐药蛋白基因表达与紫杉醇脂质体联合顺铂治疗非小细胞肺癌疗效关系的探讨 被引量:2

Research of the relationship between the clinical effects of paclitaxel liposome with DDP and expression of lung cancer resistance protein genes(LRP) in non-small cell lung cancer
在线阅读 下载PDF
导出
摘要 目的探讨肺耐药蛋白基因(LRP)在非小细胞肺癌(NSCLC)中的表达与化疗疗效之间的关系。方法采用免疫组织化学S-P法对47例NSCLC经气管镜活检组织进行LRP表达水平的检测;采用TP方案化疗:紫杉醇脂质体135mg/m2,d1、d8,顺铂80mg/m2,d1,3周为1周期,化疗2周期后评价疗效。结果NSCLC中LRP的表达阳性率为61.70%,在肺腺癌和肺鳞癌中的表达阳性率分别为76.92%和42.86%(P<0.05),LRP表达水平与TNM分期无关(P>0.05)。TP方案化疗2个周期后总有效率为42.55%,其中LRP表达阳性和阴性的有效率分别为27.59%和66.67%(P<0.01)。结论LRP在NSCLC中存在不同程度的表达,其表达在肺腺癌和肺鳞癌之间有差异,并与TP方案化疗的近期疗效相关。 Objective To investigate the relationship between the expression level of lung cancer resistance protein(LRP) and the clinical effects on non-small cell lung cancer(NSCLC) tissues by bronchoscopy biopsy.Methods The expression of LRP was detected in 47 cases of NSCLC tissues through bronchoscopy biopsy or lymphaden biopsy tissues by streptavidin-biotin-peroxidase(S-P) immunohistochemistry technique,and observed the relationship between the expression level of LRP and their clinical effects after two cycles' chemiotherapy treated by TP regimen.Results The positive expression rates of LRP on NSCLC was 61.70%.The positive expression positive rates of LRP in the adenocarcinoma and squamous carcinoma were 76.92% and 42.86% respectively.There was statistic difference in LRP expression compared with adenocarcinoma and squamous carcinoma(P〈0.05).No significance of difference was observed in LRP positive expression rates in different TNM staging of lung cancer(P〉0.05).The total clinical effective rates was 42.55% after two cycles chemiotherapy treated by TP regimen and the clinical effective rates were 27.59% and 66.67% respectively between the positive expression of LRP and negative expression of LRP,and there was statistic difference in those two groups(P〈0.01).Conclusion There was different degree expression of LRP in NSCLC and also statistic difference in LRP expression level compared with adenocarcinoma and squamous carcinoma,as well as in clinical effects after treated with TP regimen.There was statistic difference between the negative expression of LRP and positive expression of LRP.
出处 《临床肿瘤学杂志》 CAS 2010年第3期215-217,共3页 Chinese Clinical Oncology
基金 河北省重点发展学科资助项目(20042761595)
关键词 非小细胞肺癌 肺耐药蛋白基因 紫杉醇酯质体 顺铂 免疫组化 化学治疗 Non-small cell lung cancer LRP Paclitaxel liposome Cisplatin Immunohistochemistry Chemeotherapy
  • 相关文献

参考文献7

二级参考文献38

  • 1王哲海,孔莉.老年人非小细胞肺癌化疗的研究近况[J].中华老年医学杂志,2005,24(12):932-935. 被引量:7
  • 2杨爱珍,李军,徐海军,陈惠英.紫杉醇脂质体的体内外抗肿瘤作用研究[J].中国肿瘤,2006,15(12):862-864. 被引量:17
  • 3刘斌.紫杉醇新剂型——紫杉醇脂质体(力扑素)临床应用观察[J].中国医院用药评价与分析,2007,7(1):59-60. 被引量:25
  • 4Jemal A, Murray T, Ward E, et al. Cancer statistics 2006 [ J ]. CA Cancer J Clin, 2006, 56(2) : 106 -130.
  • 5Extermann M. Measuring eomorbidity in older eancer patients[J].Eur J Cancer, 2000, 36(4):453-471.
  • 6Gridelli C, Francesco P, Ciro G, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase Ⅲ randomized trial[J]. J National Cancer Institute, 2003,95 (5) :362 -372.
  • 7Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents [ J ]. Crit Rev Ther Drug Carrier Syst, 2001, 18: 567 - 606.
  • 8Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation[J]. EJPB, 2005,59(1 ): 177 - 187.
  • 9The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer[ J]. J National Cancer Institute, 1999, 91(1): 66-72.
  • 10Kudoh S, Takeda K, Nakagawa K, et al. Phase Ⅲ study of docetaxel compared with vinorelbine in elderly patients with advanced non small-cell lung cancer: results of the west Japan thoracic oncology group trial ( WJTOG 9904 ) [ J ]. J Clin Oncol, 2006, 24(22): 3657-3663.

共引文献31

同被引文献21

  • 1陈元鸿,王婉梅,王皓,李红艳.埃索美拉唑三联与奥美拉唑三联疗法治疗Hp阳性十二指肠溃疡对比研究[J].第一军医大学学报,2005,25(8):1045-1047. 被引量:82
  • 2宋晓荣,姬明丽.LRP的表达与非小细胞肺癌耐药性的关系[J].齐齐哈尔医学院学报,2006,27(4):393-395. 被引量:4
  • 3黄锡梅,苏炳光,吴春林.TP与NP方案治疗晚期非小细胞肺癌对比观察[J].实用全科医学,2007,5(4):306-307. 被引量:4
  • 4Bouhamyia L,Chantot-Bastaraud S,Zaidi S,et al.Immunolo-ealization and cell expression of lung resistance related protein(LRP)in normal and tumoral human respiratory ceils[J].JHC, 2007,55(8):773.
  • 5Scherffer GL,W ijrgaard Pl, FlensMJ,et al.The drug resestance-related protein LRP is the human major vault protein[J].NatMed, 1995, 1 : 578.
  • 6Kawnbate S, Oka M, Shiozawa K,et al. Breast cancer resistance protein directly confers SN 38 resistance of lung cancer cells [J]. Biochem Biophys Res Common, 2001,280(5) : 1216.
  • 7Rybarova S, Hajdukova M, Hodorova I, et a.l Expression of themultidrug resistanee-assoeiated protein l(MRP1)and the lung resist-ance-related protein(LRP) in human lung cancer[J].Neoplasma,2004, 51(3):169.
  • 8Scheper GI, Schroeijers AB, Izquierdo MA,et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer [J].Curr Opin Oncol,2000,12(6):550.
  • 9Herlevsen M ,Oxford G,Owens CR,et al.Depletion of major vault protein increases doxombicin sensitivity and nuclear at-cumulation and disrupts its sequestration in lysosomes[J].Mol Cancer Ther, 2007, 6(6) : 1804.
  • 10Meschini S, Macra M, Calcabrini A, et al.Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells[J].Toxicol in Vitro,2002,16(4) : 389.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部